Retifanlimab for treating anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]
Discontinued
Reference number: GID-TA10698
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid February 2022.